These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9272409)

  • 1. Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?
    Vormfelde SV; Bitsch A; Meineke I; Gundert-Remy UM; Gleiter CH
    Eur J Clin Pharmacol; 1997; 52(5):387-90. PubMed ID: 9272409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.
    Bergmann TK; Bathum L; Brosen K
    Eur J Clin Pharmacol; 2001 May; 57(2):123-7. PubMed ID: 11417443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.
    Baumann P; Broly F; Kosel M; Eap CB
    Pharmacopsychiatry; 1998 Mar; 31(2):72. PubMed ID: 9562213
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.
    Conus P; Bondolfi G; Eap CB; Macciardi F; Baumann P
    Pharmacopsychiatry; 1996 May; 29(3):108-10. PubMed ID: 8738315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
    Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
    Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
    Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
    Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine.
    Firkusny L; Gleiter CH
    Br J Clin Pharmacol; 1994 Apr; 37(4):383-8. PubMed ID: 8018460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression.
    Murphy GM; Pollock BG; Kirshner MA; Pascoe N; Cheuk W; Mulsant BH; Reynolds CF
    Neuropsychopharmacology; 2001 Nov; 25(5):737-43. PubMed ID: 11682257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.
    Kirchheiner J; Sasse J; Meineke I; Roots I; Brockmöller J
    Pharmacogenetics; 2003 Dec; 13(12):721-8. PubMed ID: 14646691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A risk-benefit assessment of mirtazapine in the treatment of depression.
    Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
    Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic analysis of mirtazapine.
    Grasmäder K; Verwohlt PL; Kühn KU; Dragicevic A; von Widdern O; Zobel A; Hiemke C; Rietschel M; Maier W; Jaehde U; Rao ML
    Eur J Clin Pharmacol; 2004 Sep; 60(7):473-80. PubMed ID: 15289959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
    Brown JT; Schneiderhan M; Eum S; Bishop JR
    Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.
    Grasmäder K; Verwohlt PL; Rietschel M; Dragicevic A; Müller M; Hiemke C; Freymann N; Zobel A; Maier W; Rao ML
    Eur J Clin Pharmacol; 2004 Jul; 60(5):329-36. PubMed ID: 15168101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
    Swaisland HC; Cantarini MV; Fuhr R; Holt A
    Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
    Lee SY; Ki CS; Hong KS; Kim JW
    J Korean Med Sci; 2004 Oct; 19(5):750-2. PubMed ID: 15483356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of maprotiline and its adverse effects on depressed patients.
    Kurata K; Kido H; Hasegawa M; Inoue M; Yamaguchi N
    Jpn J Psychiatry Neurol; 1987 Jun; 41(2):247-54. PubMed ID: 3437612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.